Apollo Biowellness, Inc., f/k/a Resonate Blends Announces Management Changes
Apollo Biowellness (OTC Pink: KOAN) announced significant management changes as Jim Morrison steps down as President/CEO while remaining on the Board. James W. Zimbler, previously Vice President of Corporate Finance, has been appointed as the new President/CEO.
Zimbler, who joined the company's board in March 2024, brings extensive experience in corporate restructuring and M&A. His primary focus will be on restructuring the company's balance sheet, reducing liabilities, and restoring solvency to facilitate potential merger, acquisition, or sale discussions.
The company plans to expand its Evolutionary Biologics Rx-Med Spa Dermatology Brand through new marketing partnerships with aesthetic distribution companies. Additionally, Apollo Biowellness intends to launch a new direct-to-consumer brand featuring shelf-stabilized biologic cosmetics, targeting TV Shopping and retail cosmetic markets.
Apollo Biowellness (OTC Pink: KOAN) ha annunciato significative modifiche nella gestione, con Jim Morrison che si dimette dalla carica di Presidente/CEO, pur rimanendo nel Consiglio. James W. Zimbler, precedentemente Vice Presidente della Finanza Aziendale, è stato nominato nuovo Presidente/CEO.
Zimbler, che è entrato a far parte del consiglio dell'azienda a marzo 2024, porta con sé una vasta esperienza nella ristrutturazione aziendale e nelle fusioni e acquisizioni. Il suo obiettivo principale sarà quello di ristrutturare il bilancio dell'azienda, ridurre le passività e ripristinare la solvibilità per facilitare potenziali discussioni su fusioni, acquisizioni o vendite.
L'azienda prevede di espandere il suo marchio di dermatologia Evolutionary Biologics Rx-Med Spa attraverso nuove partnership di marketing con aziende di distribuzione estetica. Inoltre, Apollo Biowellness intende lanciare un nuovo marchio diretto al consumatore che presenterà cosmetici biologici stabilizzati, mirati ai mercati della vendita al dettaglio e della TV Shopping.
Apollo Biowellness (OTC Pink: KOAN) anunció cambios significativos en la gestión, con Jim Morrison renunciando como Presidente/CEO, mientras continúa en la Junta. James W. Zimbler, anteriormente Vicepresidente de Finanzas Corporativas, ha sido nombrado nuevo Presidente/CEO.
Zimbler, quien se unió a la junta de la empresa en marzo de 2024, aporta una amplia experiencia en reestructuración corporativa y fusiones y adquisiciones. Su enfoque principal será reestructurar el balance de la empresa, reducir pasivos y restaurar la solvencia para facilitar posibles discusiones sobre fusiones, adquisiciones o ventas.
La empresa planea expandir su marca de dermatología Evolutionary Biologics Rx-Med Spa a través de nuevas asociaciones de marketing con empresas de distribución estética. Además, Apollo Biowellness tiene la intención de lanzar una nueva marca directa al consumidor que presentará cosméticos biológicos estabilizados, dirigidos a los mercados de cosméticos de venta al por menor y de TV Shopping.
아폴로 바이오웰니스 (OTC Pink: KOAN)는 짐 모리슨이 사장/CEO직을 사임하고 이사회에 남아있게 되면서 중요한 경영 변화를 발표했습니다. 제임스 W. 짐블러는 이전에 기업 재무의 부사장이었으며, 새로운 사장/CEO로 임명되었습니다.
짐블러는 2024년 3월 회사 이사회에 합류했으며, 기업 재구성 및 M&A에 대한 광범위한 경험을 가지고 있습니다. 그의 주요 초점은 회사의 재무제표를 재구성하고, 부채를 줄이며, 잠재적인 합병, 인수 또는 판매 논의를 촉진하기 위해 지급 능력을 회복하는 것입니다.
회사는 새로운 마케팅 파트너십을 통해 진화 생물학 Rx-Med Spa 피부과 브랜드를 확장할 계획입니다. 또한 아폴로 바이오웰니스는 TV 쇼핑 및 소매 화장품 시장을 겨냥한 선반 안정화 생물학 화장품을 특징으로 하는 새로운 소비자 직판 브랜드를 출시할 예정입니다.
Apollo Biowellness (OTC Pink: KOAN) a annoncé des changements significatifs dans sa direction, avec Jim Morrison qui démissionne de son poste de Président/CEO tout en restant au Conseil. James W. Zimbler, précédemment Vice-Président des Finances d'Entreprise, a été nommé nouveau Président/CEO.
Zimbler, qui a rejoint le conseil d'administration de l'entreprise en mars 2024, apporte une vaste expérience en restructuration d'entreprise et en fusions et acquisitions. Son principal objectif sera de restructurer le bilan de l'entreprise, de réduire les passifs et de rétablir la solvabilité pour faciliter d'éventuelles discussions sur des fusions, des acquisitions ou des ventes.
L'entreprise prévoit d'élargir sa marque de dermatologie Evolutionary Biologics Rx-Med Spa grâce à de nouveaux partenariats marketing avec des entreprises de distribution esthétique. De plus, Apollo Biowellness prévoit de lancer une nouvelle marque directe au consommateur mettant en avant des cosmétiques biologiques stabilisés, ciblant les marchés de la vente au détail et de la TV Shopping.
Apollo Biowellness (OTC Pink: KOAN) gab bedeutende Veränderungen im Management bekannt, da Jim Morrison als Präsident/CEO zurücktritt, während er im Vorstand bleibt. James W. Zimbler, zuvor Vizepräsident der Unternehmensfinanzen, wurde zum neuen Präsidenten/CEO ernannt.
Zimbler, der im März 2024 in den Vorstand des Unternehmens eintrat, bringt umfassende Erfahrung in der Unternehmensrestrukturierung und M&A mit. Sein Hauptaugenmerk wird darauf liegen, die Bilanz des Unternehmens zu restrukturieren, Verbindlichkeiten zu reduzieren und die Zahlungsfähigkeit wiederherzustellen, um potenzielle Gespräche über Fusionen, Übernahmen oder Verkäufe zu erleichtern.
Das Unternehmen plant, seine Evolutionary Biologics Rx-Med Spa Dermatologiemarke durch neue Marketingpartnerschaften mit ästhetischen Vertriebsunternehmen auszubauen. Darüber hinaus beabsichtigt Apollo Biowellness, eine neue Direktvertriebsmarke mit stabilisierten biologischen Kosmetika auf den Markt zu bringen, die sich an den Einzelhandels- und TV-Shopping-Kosmetikmarkt richtet.
- New CEO brings extensive M&A and corporate restructuring experience
- Plans to expand Evolutionary Biologics brand through new distribution partnerships
- Development of new shelf-stabilized biologic cosmetic product line
- Active pursuit of strategic partnerships and M&A opportunities
- Company requires balance sheet restructuring and return to solvency
- Significant liabilities requiring reduction through creditor negotiations
- Potential sale of company being considered, indicating possible strategic challenges
North Bergen, New Jersey--(Newsfile Corp. - March 19, 2025) - Apollo Biowellness, Inc. formerly known as Resonate Blends, Inc. (OTC Pink: KOAN) (the "Company") announces that Jim Morrison has stepped down as President/CEO of the Company. He remains a member of the Board. Mr. Morrison's actions do not in any way imply or infer that there is any dispute or disagreement relating to the Company's operations, policies or practices. Mr. Morrison is pursuing other opportunities.
Mr. James W. Zimbler, has been appointed as the new President/CEO of the Company, along with his position as a member of the Board of Directors. Mr. Zimbler was serving as the Company's Vice President of Corporate Finance and a Director since March 2024. Since July 1, 2020; he served as a Director of Emergent Health Corp. ("EMGE") from November 2017 to November 2021. December 2017 until June 2019, he served as President and a director of the predecessor iteration of a public company that is now Enzolytics, Inc., a drug development company. Since October 2024, he is the managing partner of LB Equity Advisors, Inc., a consulting company. In December 2016 he founded Emerging Growth Advisors, Inc., a consulting firm providing advisory services related to mergers and acquisitions for corporations including the Company. Prior to founding LB Equity Advisors, Inc., and Eocine Management Advisors, Inc., Mr. Zimbler served in a managerial role at other consulting firms, each specializing in mergers and acquisitions, roll ups and turn-around work.
Mr. Zimbler's role is to restructure the Company's balance sheet, capital structure and work with creditors and related parties to reduce the liabilities and return the Company to solvency in order to engage in discussions about a merger and/or acquisition or sale.
Mr. Zimbler stated, "Having a quality brand, such as Evolutionary Biologics, under the guidance of Mr. Morrison, which is the Company's Rx-Med Spa Dermatology Brand, we intend to expand into other marketing partnerships to distribute that brand through other aesthetic distribution companies. Secondarily, the Company plans to launch a new brand, geared toward the direct to consumer, TV Shopping and retail cosmetic market, with our newly developed shelf-stabilized biologic cosmetic. With these two brands we are entering into negotiations with various partners, for a possible merger, acquisition and/or sale."
About Apollo Biowellness, Inc. f/k/a Resonate Blends, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
jzimbler@emergenthealthcorp.com
www.emergenthealthcompany.com
631-806-1420
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/245174